Takeda reported the completion of the 7‑year pivotal Phase 3 TIDES trial for its live‑attenuated tetravalent dengue vaccine, QDENGA.
The trial, which enrolled more than 20,000 children and adolescents across eight dengue‑endemic countries, showed sustained protection over the full seven‑year period. Two doses of QDENGA provided 61.2% vaccine efficacy against virologically confirmed dengue at 4.5 years and 84.1% efficacy against dengue‑related hospitalizations. An exploratory booster dose analysis indicated a marginal increase in overall efficacy to 74.3% after two years, with hospitalization efficacy remaining high at 90.6%. No new safety signals were observed following the booster.
QDENGA has been authorized in 41 countries, including Indonesia, the EU, the UK, Brazil, Argentina, Thailand, and Malaysia, and was added to the World Health Organization’s List of Prequalified Vaccines. As of September 2025, 18.6 million doses had been distributed in 11 endemic countries, and Takeda is partnering with Biological E. Limited to expand manufacturing capacity to 100 million doses annually by 2030.
Takeda’s overall revenue for the last twelve months was $29.87 billion, with a gross profit margin of 64.8%. QDENGA’s revenue grew 863% in FY2024 H1, and the long‑term efficacy data are expected to accelerate approvals in additional markets, strengthen payer and clinician confidence, and support sustained revenue growth for the company.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.